Tracer library / [99mTc]HYNIC-MGS11

[99mTc]HYNIC-MGS11

Also written as [Tc-99m]Tc-HYNIC-MGS11

Radionuclide: Tc-99m t½ 360.6 min
Modality: SPECT
Production route: —
Stage: Reported once
Syntheses indexed: 1

Thyroid cancer Radioguided / image-guided surgery (intraoperative)

What it is

Compound class: HYNIC-conjugated minigastrin analog (CCK2R-targeting radiopeptide)
Target / mechanism: Cholecystokinin-2 receptor (CCK2R) targeting PMID 30650563
Clinical application: Medullary thyroid carcinoma and other CCK2R-expressing tumors PMID 30650563
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	>95%	HYNIC-MGS11	30650563 2019 Pharmaceuticals (Basel) 99mTc-labeling was performed using a previously described exchange labeling approach with tricine and EDDA

Need this precursor?We can point you to suppliers for [99mTc]HYNIC-MGS11, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 30650563. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 30650563: 'HYNIC-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-(N-Me)1-Nal-NH2 (HYNIC-MGS11)'. | Stage 28: added indication(s) oth-radioguided-surgery from consolidated missing-rubric review. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: Tc-99m is a gamma emitter used only for SPECT imaging. Linked articles: PMID 30650563.